comparemela.com

Latest Breaking News On - Rahul sarugaser - Page 7 : comparemela.com

WELL Health has a 69 per cent upside, says Raymond James

Look for digital healthcare provider WELL Health Technologies to open up the M&A tap over the next couple of quarters, says Raymond James analyst Rahul Sarugaser, who maintained an Outperform rating in a Monday report.

DRI Healthcare wins a target raise from Raymond James

Raymond James analyst Rahul Sarugaser kept an Outperform rating on DRI Healthcare Trust in a Monday update and raised his target to $16.00.

Profound Medical Corp (NASDAQ:PROF) Q1 2023 Earnings Call Transcript

Operator: Good day and thank you for standing by. Welcome to the Profound Medical First Quarter 2023 Financial Results Conference Call. At this time, all participants are in a listen-only mode.

Ginkgo Bioworks is a Buy, says Raymond James

Raymond James analyst Rahul Sarugaser is staying optimistic on Ginkgo Bioworks, saying in a Friday report it’s still early innings for the cell design company.

Medexus gets a target increase from Raymond James

Québec-based specialty pharma company Medexus Pharmaceuticals received a target price increase from Raymond James on Thursday after securing a new bank debt.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.